CT ENTERPRISE announced a positive profit forecast, expecting a comprehensive profit attributable to shareholders of approximately USD 23.5 million for the first three quarters, an increase compared to the same period last year
CT ENTERPRISE expects that the consolidated profit attributable to shareholders for the first three quarters ending September 30, 2025, will be approximately USD 23.5 million, a significant increase year-on-year, mainly due to revenue growth and the successful implementation of sales strategies for major clients. However, due to the slowdown in China's livestock industry, the demand for veterinary pharmaceutical products has decreased in the third quarter of 2025, and it is expected that the consolidated profit attributable to shareholders for that quarter will drop to approximately USD 6.5 million
According to the announcement from CT ENTERPRISE (03839), the group expects to achieve an unaudited consolidated profit attributable to shareholders of approximately USD 23.5 million for the nine months ending September 30, 2025 (2025 nine months), compared to USD 4.3 million for the nine months ending September 30, 2024 (2024 nine months). The increase in profit is mainly due to a significant rise in revenue, reflecting our successful implementation of key strategies for developing major customer sales.
However, due to the slowdown in China's livestock industry, the demand for our veterinary pharmaceutical products has also decreased since the third quarter of 2025. The group expects the unaudited quarterly consolidated profit attributable to shareholders for the three months ending September 30, 2025, to drop to approximately USD 6.5 million, compared to USD 9.3 million for the three months ending June 30, 2025
